However, the current cardiac risk prediction algorithms, such as the Framingham Risk Score (23), may hardly accurately estimate the cardiac risk for patients with BC who receive cardiotoxic anticancer agents (especially those treated with anthracycline-based chemotherapy or human epidermal growth factor receptor 2-targeted agents) (17, 18, 46, 47). This evidence concerns the gene ERBB2 and breast cancer.